Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Author:
Affiliation:
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Publisher
Korean Association for the Study of Intestinal Diseases
Subject
Gastroenterology
Link
https://synapse.koreamed.org/pdf/10.5217/ir.2017.15.2.147
Reference10 articles.
1. Changing epidemiological trends of inflammatory bowel disease in Asia
2. Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data
3. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease
4. Second Korean guidelines for the management of Crohn's disease
5. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease;World Journal of Stem Cells;2024-03-26
2. Epidemiology, Disease Course, and Clinical Outcomes of Perianal Fistulas and Fissures Crohn’s Disease: A Nationwide Population-Based Study in Taiwan;Crohn's & Colitis 360;2023-07-01
3. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies;BMC Gastroenterology;2022-12-29
4. Surgical options for perianal fistula in patients with Crohn's disease: A comparison of seton placement, fistulotomy, and stem cell therapy;Asian Journal of Surgery;2021-11
5. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational study;Stem Cell Research & Therapy;2021-07-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3